Sublingual Immunotherapy (SLIT): The Complete Guide

Sublingual immunotherapy means allergen immunotherapy given under the tongue. Sublingual literally refers to beneath the tongue, and immunotherapy refers to treatment that works by adjusting the immune response. So sublingual immunotherapy is treatment that places a controlled dose of your allergens under the tongue daily to gradually reduce how strongly your immune system reacts to them. It is commonly abbreviated SLIT and is often called allergy drops in its liquid form. Unlike antihistamines, which relieve symptoms temporarily, SLIT aims to address the underlying allergic response over a multi-year course. It is the under-the-tongue alternative to allergy shots, which deliver the same idea by injection. Outcomes vary from person to person and are not guaranteed.

It depends on the form. FDA-approved sublingual immunotherapy exists only as specific prescription tablets, namely Grastek, Oralair, Ragwitek, and Odactra, each cleared for a single allergen. The liquid allergy drops that many clinics and telehealth services provide are different: they are compounded, can cover multiple allergens, and are used off-label, which means they are not FDA-approved. Off-label use is legal and common in medicine, but it is important to understand the distinction. If a source claims FDA-approved allergy drops, that is inaccurate, because only the tablets carry FDA approval. Always confirm which form you are considering, since the regulatory status, allergen coverage, and insurance treatment differ between tablets and drops.

The core idea is the same, but the route differs. Both sublingual immunotherapy and allergy shots, formally subcutaneous immunotherapy or SCIT, deliver controlled, repeated allergen exposure to gradually reduce allergic sensitivity over years. Allergy shots use injections, usually given at a clinic, while sublingual immunotherapy is taken under the tongue and can be done at home. Because of the route, SLIT carries a lower risk of systemic reactions than shots, and its side effects are mostly mild and local, such as mouth itching. Shots have a longer track record and more single-allergen FDA approvals, while sublingual drops offer at-home convenience and multi-allergen flexibility. The better option depends on your allergens, lifestyle, and your provider's recommendation; neither is universally superior.

Sublingual immunotherapy is generally considered for people with confirmed allergic rhinitis, allergic conjunctivitis, or allergic asthma whose symptoms are driven by specific identifiable allergens such as pollen, dust mites, mold, or pet dander, especially when symptom medications are not enough or when someone wants to address the allergy itself. Candidacy starts with allergy testing to confirm what you react to, since immunotherapy is allergen-specific. Certain conditions are contraindications, including uncontrolled or severe asthma and eosinophilic esophagitis. A clinician evaluates your history, test results, and overall health before recommending treatment. Because individual factors matter, a personalized medical assessment is essential rather than a self-diagnosis, and outcomes vary between patients.

Sublingual immunotherapy is a gradual treatment, not a fast-acting one, so it is normal not to feel a difference in the first days or weeks. Many people begin to notice reduced symptoms over several months, often during their first full allergy season on treatment, though this varies considerably from person to person. The broader goal is a durable change in how your immune system responds, which is why a typical course runs three to five years. Stopping early can limit how lasting the benefit is. If you are not noticing any change after a reasonable period, that is worth discussing with your provider, who can review your dosing, adherence, and whether the treatment remains the right fit. Patience and consistency are central to giving immunotherapy a fair chance to work, and outcomes are never guaranteed.